DK521389D0 - Praeparat til behandling af adrenoleukodystrofi - Google Patents

Praeparat til behandling af adrenoleukodystrofi

Info

Publication number
DK521389D0
DK521389D0 DK521389A DK521389A DK521389D0 DK 521389 D0 DK521389 D0 DK 521389D0 DK 521389 A DK521389 A DK 521389A DK 521389 A DK521389 A DK 521389A DK 521389 D0 DK521389 D0 DK 521389D0
Authority
DK
Denmark
Prior art keywords
pct
treatment
date sep
sec
addrenoleucodystrophy
Prior art date
Application number
DK521389A
Other languages
English (en)
Other versions
DK521389A (da
Inventor
Donald Suddaby
Keith Coupland
Original Assignee
Croda Int Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10632210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK521389(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Croda Int Plc filed Critical Croda Int Plc
Publication of DK521389D0 publication Critical patent/DK521389D0/da
Publication of DK521389A publication Critical patent/DK521389A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • C07C67/54—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation by distillation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/533—Monocarboxylic acid esters having only one carbon-to-carbon double bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Edible Oils And Fats (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
DK521389A 1988-02-23 1989-10-20 Praeparat til behandling af adrenoleukodystrofi DK521389A (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888804188A GB8804188D0 (en) 1988-02-23 1988-02-23 Pharmaceutical compositions
PCT/GB1988/000373 WO1989008095A1 (en) 1988-02-23 1988-05-13 Pharmaceutical compositions for treating adrenoleukodystrophy

Publications (2)

Publication Number Publication Date
DK521389D0 true DK521389D0 (da) 1989-10-20
DK521389A DK521389A (da) 1989-12-15

Family

ID=10632210

Family Applications (1)

Application Number Title Priority Date Filing Date
DK521389A DK521389A (da) 1988-02-23 1989-10-20 Praeparat til behandling af adrenoleukodystrofi

Country Status (10)

Country Link
US (1) US5331009A (da)
EP (1) EP0360821B1 (da)
JP (1) JPH0667869B2 (da)
AT (1) ATE86965T1 (da)
CA (1) CA1308028C (da)
DE (1) DE3879489T2 (da)
DK (1) DK521389A (da)
GB (1) GB8804188D0 (da)
NO (1) NO894083L (da)
WO (1) WO1989008095A1 (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416846D0 (en) * 1994-08-19 1994-10-12 Croda Int Plc Lipid supplementation
AU6269799A (en) 1998-09-28 2000-04-17 Johns Hopkins University, The Adrenoleukodystrophy treatments and drug screening
JP2001278786A (ja) * 2000-03-29 2001-10-10 Morinaga Milk Ind Co Ltd 高尿酸性疾患予防治療剤
CA2953319C (en) 2014-07-02 2022-11-29 Nippon Suisan Kaisha, Ltd. Production method of marine product-derived free monounsaturated fatty acids or lower alcohol esters thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442125A (en) * 1978-06-26 1984-04-10 Oxford Hill, Ltd. Process for detaching or preventing attachment of microorganisms to a surface
US4377526A (en) * 1981-05-15 1983-03-22 Nippon Suisan Kaisha, Ltd. Method of purifying eicosapentaenoic acid and its esters
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis

Also Published As

Publication number Publication date
NO894083D0 (no) 1989-10-12
JPH02503792A (ja) 1990-11-08
EP0360821A1 (en) 1990-04-04
CA1308028C (en) 1992-09-29
JPH0667869B2 (ja) 1994-08-31
ATE86965T1 (de) 1993-04-15
EP0360821B1 (en) 1993-03-17
NO894083L (no) 1989-10-12
US5331009A (en) 1994-07-19
DE3879489T2 (de) 1993-06-24
DK521389A (da) 1989-12-15
WO1989008095A1 (en) 1989-09-08
DE3879489D1 (de) 1993-04-22
GB8804188D0 (en) 1988-03-23

Similar Documents

Publication Publication Date Title
ES2173400T3 (es) Composiciones que contienen cinc para administracion oral que incluyen un compuesto de cobre y un aminoacido.
AU640137B2 (en) Novel arylpyridazines, their manufacture, use and medicaments containing them
MA23170A1 (fr) Procede de preparation d'un nouveau compose .
GR3019315T3 (en) Use of nervonic acid and long chain fatty acids for the treatment of demyelinating disorders
PT78611A (en) Process to prepare a two-phase pharmaceutical composition with niphedypine <dimethylic acid esther 1,4-di-hydro-2,6-dimethyl- 4-(2 nitrophenyl)-3,5-pyridine-dicarboxilic> in non-crystallin e and crystalline forms
AU3044492A (en) Sustained release thyroactive composition
CA2269807A1 (en) Substituted aminoalkanephosphonic acids
DK503687D0 (da) Farmaceutisk praeparat af ibuprofen
PT85591A (en) Process for the preparation of multiple unit dosage pharmaceutical compositions comprising as a pharmaceutilly active compound l-dopa
IE940326L (en) Benzimidazole derivatives substituted with a radical group¹and their use for inhibiting gastric acid secretion
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
ATE55695T1 (de) Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
EP0173664A3 (en) Biologically active benzimidazole compounds and process for their preparation
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ATE88633T1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
ATE75395T1 (de) Linolensaeuren enthaltende pharmazeutische und diaet-zusammensetzungen zur behandlung von gutartiger prostatahypertrophie.
MY129946A (en) Compound with gastric acid inhibitory effect and process for its preparation.
DK521389D0 (da) Praeparat til behandling af adrenoleukodystrofi
GR890100563A (el) Προαγωγη της αναπτυξεως χοιρων.
GEP20032968B (en) Use of Ketolides in Pharmaceutical Compositions for Preventing Thrombotic Arterial Complications Linked to Atherosclerosis
DK0911038T3 (da) Vandfri sammensætning omfattende lactulose
JPS5626819A (en) Preventive for hypoimmunity
ATE73326T1 (de) Verwendung von l-carnitin zur herstellung eines arzneimittels zur behandlung von toxischen effekten, induziert durch die inhalation von halotan und anderen halogen enthaltenden allgemeinen anaesthetika.

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment